- Home
- ACRS vs ALLT Comparison
ACRS vs ALLT Comparison
Compare ACRS & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- ALLT
- Stock Information
- Founded
- ACRS 2012
- ALLT 1996
- Country
- ACRS United States
- ALLT Israel
- Employees
- ACRS N/A
- ALLT N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- ALLT Telecommunications Equipment
- Sector
- ACRS Health Care
- ALLT Telecommunications
- Exchange
- ACRS Nasdaq
- ALLT Nasdaq
- Market Cap
- ACRS 132.0M
- ALLT 149.3M
- IPO Year
- ACRS 2015
- ALLT 2006
- Fundamental
- Price
- ACRS $4.32
- ALLT $4.39
- Analyst Decision
- ACRS Buy
- ALLT Strong Buy
- Analyst Count
- ACRS 6
- ALLT 2
- Target Price
- ACRS $7.20
- ALLT $7.75
- AVG Volume (30 Days)
- ACRS 6.0M
- ALLT 203.0K
- Earning Date
- ACRS 11-06-2024
- ALLT 11-19-2024
- Dividend Yield
- ACRS N/A
- ALLT N/A
- EPS Growth
- ACRS N/A
- ALLT N/A
- EPS
- ACRS N/A
- ALLT N/A
- Revenue
- ACRS $27,079,000.00
- ALLT $91,631,000.00
- Revenue This Year
- ACRS N/A
- ALLT N/A
- Revenue Next Year
- ACRS N/A
- ALLT $10.35
- P/E Ratio
- ACRS N/A
- ALLT N/A
- Revenue Growth
- ACRS 26.35
- ALLT N/A
- 52 Week Low
- ACRS $0.77
- ALLT $1.19
- 52 Week High
- ACRS $5.17
- ALLT $4.55
- Technical
- Relative Strength Index (RSI)
- ACRS 74.71
- ALLT 71.08
- Support Level
- ACRS $3.67
- ALLT $3.47
- Resistance Level
- ACRS $5.17
- ALLT $4.28
- Average True Range (ATR)
- ACRS 0.47
- ALLT 0.27
- MACD
- ACRS 0.20
- ALLT 0.03
- Stochastic Oscillator
- ACRS 72.93
- ALLT 87.03
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. It has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.